The endocannabinoid system and its therapeutic exploitation
The DOI matches its Crossref record; 160 of the 161 references it cites were found in a registry or an index.
Abstract
The term 'endocannabinoid' - originally coined in the mid-1990s after the discovery of membrane receptors for the psychoactive principle in Cannabis, Delta9-tetrahydrocannabinol and their endogenous ligands - now indicates a whole signalling system that comprises cannabinoid receptors, endogenous ligands and enzymes for ligand biosynthesis and inactivation. This system seems to be involved in an ever-increasing number of pathological conditions. With novel products already being aimed at the pharmaceutical market little more than a decade since the discovery of cannabinoid receptors, the endocannabinoid system seems to hold even more promise for the future development of therapeutic drugs. We explore the conditions under which the potential of targeting the endocannabinoid system might be realized in the years to come.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The obvious implications are that cannabinoids and similarly acting drugs may regulate cognitive functions, modulate food intake, affect both female and male reproduction, provide neuroprotection and be involved in neurodegenerative diseases; pathophysiology of shock; inhibition of fertilized oocyte implantation; inhibition of cancer growth, angiogenesis and metastasis (for a review see ref. 71).”
From Paracetamol: New Vistas of an Old Drug (2006) · cites this paper as [71]
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 1×
“∆(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A Neuropsychopharmacology 24, 198–203 (2001).”
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011 · cited 1×
“The serendipitous cloning in 1990 of the first of such proteins, the CB 1 receptor, came from the screening of an 'orphan' G-protein-coupled receptor (GPCR) with several possible ligand”
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443 · cited 1×
“1 ), led to the identification of plasma membrane CANNABINOID RECEPTORS in 1988 (Ref”
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,393
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · cited 1×
“Functions of the endocannabinoid system The components ( Figs 3 , 4 ) and possible physiological functions of the endocannabinoid system have been extensively reviewed in recent article”
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,757
Research works printed but not linked: 4
- Mechoulam, R. in Cannabis as Therapeutic Agent (ed. Mechoulam, R.) 1–19 (CRC Press Roca Ranton, 1986). The most comprehensive history of the recreational and medicinal use of Cannabis throughout the centuries.
- Di Marzo, V., Bisogno, T., De Petrocellis, L., Berger, A. & Mechoulam, R. in Biology of Marijuana (ed. Onaivi, E.) 125–173 (Harwood Academic, Reading, 2002).
- Pertwee, R. G. in Cannabinoids (ed. Di Marzo, V.) 32–83 (Kluwer Academic, New York, 2004).
- Pop, E. Dexanabinol Pharmos. Curr. Opin. Investig. Drugs 1, 494–503 (2000).
Cited by
Items 301–400 of 1,001
TRPV1 Regulates Stress Responses through HDAC2
Wang, S. E., Ko, S. Y., Jo, S., Choi, M., Lee, S. H., Jo, H.-R., Seo, J. Y., Lee, S. H., Kim, Y.-S., Jung, S. J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.050 · Cited by 59
“One should remember, though, that EBs bind to CB1, as well as TRPV1 (Di Marzo et al., 2004).”
BackgroundRobinson, S. A., Loiacono, R. E., Christopoulos, A., Sexton, P. M., & Malone, D. T. (2010) · Brain Research · doi:10.1016/j.brainres.2010.04.031 · Cited by 59
Naderi, N., Ahari, F. A., Shafaghi, B., Najarkolaei, A. H., & Motamedi, F. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0076-x · Cited by 59
“Considering the intracellular effects after binding of cannabinoid receptor agonists to their receptors, it has been suggested that these compounds render neurons less excitable (reviewed in Di Marzo et al. 2004; Piomelli 2003).”
BackgroundBaldassarre, M., Giannone, F. A., Napoli, L., Tovoli, A., Ricci, C. S., Tufoni, M., & Caraceni, P. (2013) · Liver International · doi:10.1111/liv.12263 · Cited by 59
“As a result, it has become evident that EC provide several central and peripheral actions implicated in many biological processes such as energy balance, food intake, mood, analgesia and motor function, immune and inflammatory responses, cell proliferation, fertility, cardiovascular and gastrointestinal function (1, 3…”
BackgroundUse of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders
Scheen, A. J., & Paquot, N. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.09.001 · Cited by 59
“), leading to an explosion of basic research and clinical trials, especially in the field of metabolic disorders associated to abdominal obesity [1,8,9].”
Drugs on the horizon for diabesity
Bailey, C. J. (2005) · Current Diabetes Reports · doi:10.1007/s11892-005-0093-1 · Cited by 59
On the interaction between drugs of abuse and adolescent social behavior
Trezza, V., Baarendse, P. J. J., & Vanderschuren, L. J. M. J. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3471-z · Cited by 59
“If indirect cannabinoid agonists are used, however, only ongoing cannabinoid activity, relevant to the given situation, will be stimulated (Di Marzo et al. 2004; Piomelli 2003).”
Endocannabinoids Link Feeding State and Auditory Perception-Related Gene Expression
Soderstrom, K., Tian, Q., Valenti, M., & Marzo, V. D. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.3298-04.2004 · Cited by 58
“In humans, cannabinoids stimulate appetite and the intake of palatable food (Iversen, 2003), and accumulating evidence supports a relationship between cannabinoid signaling and feeding behavior (Di Marzo et al., 2001, 2004; Hanus et al., 2003; Matias et al., 2003; Matias and Di Marzo, 2004).”
Self-citationFrom individual risk factors and the metabolic syndrome to global cardiometabolic risk
Després, J.-P., Poirier, P., Bergeron, J., Tremblay, A., Lemieux, I., & Alméras, N. (2008) · European Heart Journal Supplements · doi:10.1093/eurheartj/sum041 · Cited by 46
“The discovery of the endocannabinoid (EC) system and its impact on energy balance, body fat distribution, and lipid/carbohydrate metabolism has been a fascinating breakthrough.(83,84) Recent evidence has highlighted that viscerally obese patients are the subgroup of individuals with an activated EC system.”
BackgroundHa, Y., Jeong, I., & Kim, T. H. (2022) · Biomedicines · doi:10.3390/biomedicines10102530 · Cited by 57
Ayub, M., Jin, H.-K., & Bae, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147353 · Cited by 57
“However, endocannabinoids function by binding to their specific receptors (type-1 and type-2 cannabinoid receptors) and serve to maintain the homeostatic environment of the respective tissues [6].”
BackgroundCannabinoids, Insomnia, and Other Sleep Disorders
Lavender, I., McGregor, I. S., Suraev, A. S., Grunstein, R. R., & Hoyos, C. M. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.04.151 · Cited by 57
The Endocannabinoid System: Current Pharmacological Research and Therapeutic Possibilities
Jonsson, K., Holt, S., & Fowler, C. J. (2006) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2006.pto_376.x · Cited by 57
Rubio‐Araiz, A., Arévalo‐Martín, Á., Gómez, O., Navarro‐Galve, B., García‐Ovejero, D., Suetterlin, P., Sánchez-Heras, E., Molina‐Holgado, E., & Molina‐Holgado, F. (2008) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2008.03.010 · Cited by 56
“In the brain, the endocannabinoid system is composed of two well characterized lipid mediators, N-arachidonoylethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG), ligands of the CB1 and CB2 cannabinoid receptors (Di Marzo et al., 2004).”
BackgroundHollander, P. A. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.11.014 · Cited by 56
Löfgren, P., Sjölin, E., Wåhlén, K., & Hoffstedt, J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2240 · Cited by 56
“Both CB receptors belong to the family of G-coupled receptors that after ligand binding modulates the activity of various cell-signaling cascades including adenylate cyclase- and mitogen-activated protein kinase-related events ( 2 ).”
BackgroundWu, K., Xiu, Y., Zhou, P., Qiu, Y., & Li, Y. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00818 · Cited by 55
“AEA is an agonist of CB2 receptor (Zygmunt et al., 1999; Di Marzo et al., 2004).”
BackgroundEndocannabinoids Control Platelet Activation and Limit Aggregate Formation under Flow
Angelis, V. D., Koekman, A. C., Weeterings, C., Roest, M., de Groot, P. G., Herczenik, E., & Maas, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108282 · Cited by 55
“For these therapeutic purposes, the development of peripherally restricted and non-psychoactive pharmacological endocannabinoid analogues is warranted [25].”
BackgroundPatrician, A., Bratinčević, M. V., Mijačika, T., Banić, I., Marendić, M., Sutlović, D., Dujić, Ž., & Ainslie, P. N. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01074-6 · Cited by 55
Chesterfield, A. K., Kidd, S. R., Moore, S. A., Schaus, J. M., Liu, B., Nomikos, G. G., & Felder, C. C. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9072-6 · Cited by 55
“The effects of the principal active phytocannabinoid in marijuana, 9-tetrahydrocannabinol ( 9-THC), in the central nervous system (CNS) and periphery have been extensively reviewed (Di Marzo et al., 2004; Fowler et al., 2005; Howlett et al., 2004; Iversen, 2004).”
BackgroundLack of association of genetic variants in genes of the endocannabinoid system with anorexia nervosa
Müller, T. D., Reichwald, K., Brönner, G., Kirschner, J., Nguyen, T. T., Scherag, A., Herzog, W., Herpertz‐Dahlmann, B., Lichtner, P., Meitinger, T., et al. (2008) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-2-33 · Cited by 55
Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty
Vasincu, A., Rusu, R.-N., Ababei, D. C., Larion, M., Bild, W., Stanciu, G. D., Solcan, C., & Bild, V. (2022) · Biology · doi:10.3390/biology11030440 · Cited by 54
Mode of action of cannabinoids on nociceptive nerve endings
Kress, M., & Kuner, R. (2009) · Experimental Brain Research · doi:10.1007/s00221-009-1762-0 · Cited by 54
“Initially, CB2 receptors were reported to localise mainly in lymphoid tissue in the periphery ( Di Marzo et al. 2004; Munro et al. 1993), although recent studies suggest CB2 expression in rodent brain and in microglia in postmortem human material from regions aVected by multiple sclerosis and amyotrophic lateral scler…”
BackgroundDoes cannabidiol have a role in the treatment of schizophrenia?
Gururajan, A., & Malone, D. T. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.06.022 · Cited by 54
“The endocannabinoid system in the brain has been implicated in mediating several important functions including appetite and mood regulation as well as reward processing (Di Marzo et al., 2004).”
Watanabe, T., Kubota, N., Ohsugi, M., Kubota, T., Takamoto, I., Iwabu, M., Awazawa, M., Katsuyama, H., Hasegawa, C., Tokuyama, K., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807120200 · Cited by 53
Animal models of cannabinoid reward
Panlilio, L. V., Justinová, Z., & Goldberg, S. R. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00775.x · Cited by 53
“Several endogenous cannabinoid ligands have been identified in the brain, but the best characterized of these is anandamide (Freund et al., 2003; Di Marzo et al., 2004; Piomelli, 2004).”
BackgroundKinetic analysis of the cannabinoid-1 receptor PET tracer [18F]MK-9470 in human brain
Bohorquez, S. M. S., Hamill, T. G., Goffin, K. E., Lepeleire, I. D., Bormans, G. M., Burns, H. D., & Laere, K. V. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1340-5 · Cited by 53
“Pharmacological manipulation of the CB1R is a promising approach as an adjuvant therapeutic intervention for several neuropsychiatric disorders [ 5 ].”
BackgroundReduced cerebrospinal fluid ethanolamine concentration in major depressive disorder
Ogawa, S., Hattori, K., Sasayama, D., Yokota, Y., Matsumura, R., Matsuo, J., Ota, M., Hori, H., Teraishi, T., Yoshida, S., et al. (2015) · Scientific Reports · doi:10.1038/srep07796 · Cited by 53
Chemical Proteomics Maps Brain Region Specific Activity of Endocannabinoid Hydrolases
Baggelaar, M. P., van Esbroeck, A. C. M., van Rooden, E. J., Florea, B. I., Overkleeft, H. S., Marsicano, G., Chaouloff, F., & van der Stelt, M. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b01052 · Cited by 52
Sarott, R. C., Westphal, M. V., Pfaff, P., Korn, C., Sykes, D. A., Gazzi, T., Brennecke, B., Atz, K., Weise, M., Mostinski, Y., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c05587 · Cited by 53
Development of Radioligands for In Vivo Imaging of Type 1 Cannabinoid Receptors (CB1) in Human Brain
Horti, A. G., & Laere, K. V. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208786549380 · Cited by 53
Σκρέτας, Γ., & Georgiou, G. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.22097 · Cited by 53
“CB1 is one of the most highly expressed GPCRs in the central nervous system and along with the peripheral cannabinoid receptor (CB2) forms the core of the so-called ‘‘endocannabinoid system’’ (Di Marzo et al., 2004).”
Mick, I., Freger, S., van Keizerswaard, J., Gholiof, M., & Leonardi, M. (2024) · Therapeutic Advances in Reproductive Health · doi:10.1177/26334941241277759 · Cited by 52
Localization and production of peptide endocannabinoids in the rodent CNS and adrenal medulla
Hofer, S. C., Ralvenius, W. T., Gachet, M. S., Fritschy, J., Zeilhofer, H. U., & Gertsch, J. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.03.021 · Cited by 52
Nicotine and Non-nicotine Smoking Cessation Pharmacotherapies
Frishman, W. H., Mitta, W., Kupersmith, A., & Ky, T. (2006) · Cardiology in Review · doi:10.1097/01.crd.0000172309.06270.25 · Cited by 50
Molecular mechanisms of cannabinoid addiction
Fratta, W., & Fattore, L. (2013) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2013.02.002 · Cited by 51
“com 1 (CB1R) is the most abundant in the brain, secondly, endogenous ligands for CBRs, like anandamide and 2arachidonylglycerol, thirdly, a putative membrane transporter, and finally, enzymes involved in the synthesis and inactivation of the endogenous ligands [6,7].”
BackgroundCannabinoid CB 1 receptors mediate the effects of dipyrone
Crunfli, F., Vilela, F. C., & Giusti‐Paiva, A. (2015) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12347 · Cited by 51
“Inhibition of COX-1 and COX-2 by dipyrone can be accomplished by activation of cannabinoid receptors (CB1 and CB2), suggesting that these receptors are candidate targets for the development of analgesic drugs.(61) G€uhring et al.”
BackgroundDiscovery and Development of Endocannabinoid-Hydrolyzing Enzyme Inhibitors
Minkkilä, A., Saario, S. M., & Nevalainen, T. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610791164238 · Cited by 51
Addy, C., Rothenberg, P., Li, S., Majumdar, A. K., Agrawal, N. G. B., Li, H., Zhong, L., Yuan, J., Maes, A. L., Dunbar, S. A., et al. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008317591 · Cited by 51
“Endocannabinoids represent important physiologic regulators of energy balance(5-9) and promote appetite and food intake through activation of central CB1R (Figure 1).(6,8,10) CB1R inverse agonists have the opposite effect of endocannabinoids, inhibiting food intake, increasing energy expenditure, and reducing body wei…”
BackgroundDifferential regulation of Ca v 3.2 and Ca v 2.2 calcium channels by CB 1 receptors and cannabidiol
Harding, E. K., Souza, I. A., Gandini, M. A., Gadotti, V. M., Ali, M. Y., Huang, S., Antunes, F. T. T., Trang, T., & Zamponi, G. W. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16035 · Cited by 50
“…by G protein-coupled receptors is well documented and typically involves the induction of a reluctant gating state by binding of the G protein βγ dimer to the pore forming α1 sub- unit of the channel (di Marzo et al., 2004; Mackie & Hille, 1992; Tedford & Zamponi, 2006; Twitchell et al., 1997).”
BackgroundTranslational potential of allosteric modulators targeting the cannabinoid CB1 receptor
Lu, D., Immadi, S. S., Wu, Z., & Kendall, D. A. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0164-x · Cited by 50
Effects of endocannabinoid neurotransmission modulators on brain stimulation reward
Vlachou, S., Nomikos, G. G., & Panagis, G. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0506-0 · Cited by 50
“These observations have contributed to expectations that modulating endocannabinoid levels for therapeutic purposes would have minimal psychotropic effects and abuse liability (Martin 2002; Piomelli 2003, 2004; Di Marzo et al. 2004; Ortega-Gutiérrez 2005; Pertwee 2005).”
BackgroundEisenstein, S. A., Clapper, J. R., Holmes, P. V., Piomelli, D., & Hohmann, A. G. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2009.12.013 · Cited by 49
“CB1 and CB2 receptors belong to a family of Gi/o-protein-coupled receptors and engage complex signaling mechanisms [3].”
BackgroundInfluentialKonermann, A., Jäger, A., Held, S. A. E., Brossart, P., & Schmöle, A. (2017) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-017-0482-4 · Cited by 49
“Investigations already revealed an involvement of CB2 receptors in the establishment of nociceptive and inflammatory states in terms of anti-inflammatory pathway activation and thus immunosuppressive action (Di Marzo et al. 2004; Ihenetu et al. 2003).”
Reddy, V. P., Grogan, D. P., Ahluwalia, M., Salles, É. L., Ahluwalia, P. K., Khodadadi, H., Alverson, K., Nguyen, A., Raju, S. P., Gaur, P., et al. (2020) · The EPMA Journal · doi:10.1007/s13167-020-00203-4 · Cited by 49
Radiochromatographic assay of N-acyl-phosphatidylethanolamine-specific phospholipase D activity
Fezza, F., Gasperi, V., Mazzei, C., & Maccarrone, M. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2004.12.005 · Cited by 49
The role of the endocannabinoid system in the regulation of energy homeostasis
Cota, D., & Woods, S. C. (2005) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000178715.87999.69 · Cited by 40
Aziz, A.-I., Nguyen, L. C., Oumeslakht, L., Bensussan, A., & Mkaddem, S. B. (2023) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0133 · Cited by 48
Addy, C., Li, S., Agrawal, N. G. B., Stone, J. A., Majumdar, A. K., Zhong, L., Li, H., Yuan, J., Maes, A. L., Rothenberg, P., et al. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008314467 · Cited by 48
“Of the 198 clinical AEs reported, the most common clinical drug-related AEs were nausea (36), headache (22), drowsiness (14), abdominal discomfort/abdominal pain/stomachache (14), hiccups (9), dizziness (8), decreased appetite (7), increased bowel movement (7), mood change (6), tiredness (4), vomiting (4), and sweatin…”
BackgroundThe endocannabinoid 2-AG enhances spontaneous remyelination by targeting microglia
Mecha, M., Yanguas-Casás, N., Feliú, A., Mestre, L., Carrillo-Salinas, F., Azcoitia, I., Yong, V. W., & Guaza, C. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.12.013 · Cited by 47
Bioactive signalling lipids as drivers of chronic liver diseases
Kaffe, E., Tisi, A., Magkrioti, C., Aidinis, V., Mehal, W. Z., Flavell, R. A., & Maccarrone, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.029 · Cited by 47
The Endocannabinoid System: A Putative Role in Neurodegenerative Diseases
Iorio, G. D., Lupi, M., Sarchione, F., Matarazzo, I., Santacroce, R., Petruccelli, F., Martinotti, G., & Giannantonio, M. D. (2013) · international journal high risk behaviors & addiction · doi:10.5812/ijhrba.9222 · Cited by 47
“FAAH is designed to degrade AEA, MAGL instead catalyzes 2-AG breakdown (7, 8) (Figure 1).”
BackgroundTabrizi, M. A., Baraldi, P. G., Ruggiero, E., Saponaro, G., Baraldi, S., Poli, G., Tuccinardi, T., Ravani, A., Vincenzi, F., Borea, P. A., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.02.032 · Cited by 47
Jennings, J. M., Williams, M. A., Levy, D. L., Johnson, R. M., Eschen, C. L., & Dennis, D. A. (2018) · Clinical Orthopaedics and Related Research · doi:10.1097/corr.0000000000000339 · Cited by 47
“Marijuana may function to reduce sensitization of the nociceptive sensory pathways and induce alterations in cognitive and autonomic processing in chronic pain conditions [6, 12].”
The endocannabinoid system and stroke: A focused review
Rajah, G. B., Kolb, B. L., Saber, H., & Fadel, H. A. (2019) · Brain Circulation · doi:10.4103/bc.bc_29_18 · Cited by 47
“Alteration of the endocannabinoid signaling system has been implicated in a vast array of human diseases, including neurological disorders such as Parkinson’s, Alzheimer’s, and multiple sclerosis.[9] Recent evidence has shown that simple medicinal cannabis formulations can function as efficacious neuroprotectants.”
BackgroundLadha, K. S., Ajrawat, P., Yang, Y., & Clarke, H. A. (2020) · Molecules · doi:10.3390/molecules25184042 · Cited by 47
Bilbao, A., Blanco, E., Rojas, M. J. L., Suárez, J., Palomino, A., Vida, M., Araos, P. F., Bermúdez‐Silva, F. J., Fernández‐Espejo, E., Spanagel, R., et al. (2012) · Addiction Biology · doi:10.1111/adb.12006 · Cited by 47
Jaeger, J. P., Mattevi, V. S., Callegari-Jacques, S. M., & Hutz, M. H. (2008) · Disease Markers · doi:10.1155/2008/841490 · Cited by 47
Endocannabinoid signaling in neurotoxicity and neuroprotection
Pope, C., Mechoulam, R., & Parsons, L. H. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2009.12.002 · Cited by 47
“The eCBs are synthesized “on demand” from arachidonic acid of membrane phospholipids [8].”
BackgroundVerdurand, M., Nguyen, V., Stark, D., Zahra, D., Gregoire, M.-C., Greguric, I., & Zavitsanou, K. (2011) · International Journal of Molecular Imaging · doi:10.1155/2011/548123 · Cited by 41
“The concentration of CB2R in the rat brain is supposed to be small in comparison to CB1R [3, 56, 57].”
BackgroundNew Natural Noncannabinoid Ligands for Cannabinoid Type-2 (CB2) Receptors
Gertsch, J., Raduner, S., & Altmann, K. (2006) · Journal of Receptors and Signal Transduction · doi:10.1080/10799890600942674 · Cited by 47
Liver Fatty Acid-binding Protein Binds Monoacylglycerol in Vitro and in Mouse Liver Cytosol
Lagakos, W., Guan, X., Ho, S., Sawicki, L. R., Córsico, B., Kodukula, S., Murota, K., Stark, R. E., & Storch, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.473579 · Cited by 46
“In particular, 2-arachidonoylglycerol has attracted much attention as an endogenous cannabinoid receptor ligand (3, 4).”
BackgroundHan, S., Thoresen, L. H., Jung, J., Zhu, X., Thatte, J., Solomon, M., Gaidarov, I., Unett, D. J., Yoon, W. H., Barden, J., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00396 · Cited by 46
Ebersbach, P., Stehle, F., Kayser, O., & Freier, E. (2018) · BMC Plant Biology · doi:10.1186/s12870-018-1481-4 · Cited by 46
Health benefits of 4,4-dimethyl phytosterols: an exploration beyond 4-desmethyl phytosterols
Zhang, T., Liu, R., Chang, M., Jin, Q., Zhang, H., & Wang, X. (2019) · Food & Function · doi:10.1039/c9fo01205b · Cited by 46
Zhao, P., Leonoudakis, D., Abood, M. E., & Beattie, E. C. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.07.035 · Cited by 46
“It is possible that activation of CB1 may counter this TNFa-induced AMPAR surface delivery through an intracellular signaling mechanism that decreases PKA activation (Di Marzo et al., 2004; Kim et al., 2006; Wade et al., 2004).”
BackgroundNilsson, O., Fowler, C. J., & Jacobsson, S. O. P. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.07.016 · Cited by 46
Analgesic Effect of a Mixed T-Type Channel Inhibitor/CB2 Receptor Agonist
Gadotti, V. M., You, H., Petrov, R. R., Berger, N. D., Diaz, P., & Zamponi, G. W. (2013) · Molecular Pain · doi:10.1186/1744-8069-9-32 · Cited by 45
“side effects [35,36].”
Simultaneous HPLC-APCI-MS/MS quantification of endogenous cannabinoids and glucocorticoids in hair
Mwanza, C., Zheng, C., Zhang, Q., Chen, S., Wang, W., & Deng, H. (2016) · Journal of Chromatography B · doi:10.1016/j.jchromb.2016.06.002 · Cited by 45
Ferber, S. G., Trezza, V., & Weller, A. (2019) · Developmental Psychobiology · doi:10.1002/dev.21944 · Cited by 45
The Endocannabinoid System: A New Molecular Target for the Treatment of Tobacco Addiction
Scherma, M., Fadda, P., Foll, B. L., Forget, B., Fratta, W., Goldberg, S. R., & Tanda, G. (2008) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152708786927859 · Cited by 45
Rawas, R. E., Thiriet, N., Nader, J., Lardeux, V., Jaber, M., & Solinas, M. (2011) · Brain Research · doi:10.1016/j.brainres.2011.03.025 · Cited by 45
“…alters mRNA expression of CB1 and FAAH but not of MGL. FAAH enzymes are responsible for the degradation of anandamide (Cravatt and Lichtman, 2003; Di Marzo et al., 2004; Piomelli, 2003; Ueda et al., 2000) whereas MGL enzymes are responsible for the degradation of 2-AG (Di Marzo et al., 2004;…”
InfluentialEffect of a synthetic cannabinoid agonist on the proliferation and invasion of gastric cancer cells
Xian, X., Park, H., Cho, Y. K., Lee, I. S., Kim, S. W., Choi, M., Chung, I., Han, K., & Park, J. M. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22540 · Cited by 45
“Cannabinoids act by activating specific cell surface G-protein-coupled cannabinoid receptors [Di Marzo et al., 2004].”
BackgroundSido, J. M., Nagarkatti, P. S., & Nagarkatti, M. (2014) · International Reviews of Immunology · doi:10.3109/08830185.2014.921165 · Cited by 44
“[50] Di Marzo V, Bifulco M, De Petrocellis L.”
BackgroundPerspectives on Challenges in Cannabis Drug Delivery Systems: Where Are We?
Palrasu, M., Wright, L. H., Patel, M. P., Leech, L., Branch, S., Harrelson, S., & Khan, S. R. (2022) · Medical Cannabis and Cannabinoids · doi:10.1159/000525629 · Cited by 44
Schmidt, W., Schäfer, F., Striggow, V., Fröhlich, K., & Striggow, F. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.080 · Cited by 44
Zanfirescu, A., Ungurianu, A., Mihai, D. P., Radulescu, D., & Nițulescu, G. M. (2021) · Molecules · doi:10.3390/molecules26185668 · Cited by 43
“cardiovascular functions [6,7], by activating CB2R receptors and other targets (peroxisome proliferator-activated receptors, transient receptor potential vanilloid-1) [7] (Figure 1).”
BackgroundCannabis sativaand the Endogenous Cannabinoid System: Therapeutic Potential for Appetite Regulation
Farrimond, J. A., Mercier, M. S., Whalley, B. J., & Williams, C. M. (2011) · Phytotherapy Research · doi:10.1002/ptr.3375 · Cited by 43
“Endocannabinoids (AEA and 2‐AG) are produced on demand by postsynaptic neurons (Di Marzo et al., 2004) in the CNS in response to rises in intracellular [Ca2+] (Cadas et al., 1997; Di Marzo et al., 1994).”
BackgroundJanero, D. R., Vadivel, S. K., & Makriyannis, A. (2009) · International Review of Psychiatry · doi:10.1080/09540260902782778 · Cited by 43
An expeditious hydroxyamidation of carboxylic acids
Ech‐Chahad, A., Minassi, A., Berton, L., & Appendino, G. (2005) · Tetrahedron Letters · doi:10.1016/j.tetlet.2005.05.131 · Cited by 43
Sharkey, K. A., & Pittman, Q. J. (2005) · Science's STKE · doi:10.1126/stke.2772005pe15 · Cited by 36
Cannabinoids—Multifunctional Compounds, Applications and Challenges—Mini Review
Duczmal, D., Bazan‐Wozniak, A., Niedzielska, K., & Pietrzak, R. (2024) · Molecules · doi:10.3390/molecules29204923 · Cited by 42
Papini, S., Sullivan, G. M., Hien, D. A., Shvil, E., & Neria, Y. (2015) · Biological Psychology · doi:10.1016/j.biopsycho.2014.10.010 · Cited by 36
“…enhancing extinction learning and retention is the endogenous cannabinoid system (ECS), which includes cannabinoid receptors, endocannabinoid neurotransmitters such as anandamide, and enzymes responsible for the breakdown and reuptake of endocannabinoids (Di Marzo, Bifulco, & De Petrocellis, 2004).”
BackgroundThe cannabinoid receptor 1 and its role in influencing peripheral metabolism
O’Keefe, L., Simcocks, A. C., Hryciw, D. H., Mathai, M. L., & McAinch, A. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12144 · Cited by 42
“The first endocannabinoid ligand identified in 1992 was anandamide (AEA) [3], with AEA being synthesized following an increase in intracellular calcium (Ca2+) levels [11,16].”
BackgroundO sistema endocanabinóide: novo paradigma no tratamento da síndrome metabólica
Godoy‐Matos, A. F., Guedes, E. P., de Souza, L. L., & Valério, C. M. (2006) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302006000200025 · Cited by 42
Cumella, J., Hernández‐Folgado, L., Girón, R., Sánchez-Robles, E., Morales, P., Hurst, D. P., Gómez‐Cañas, M., Gómez‐Ruíz, M., Pinto, D. C. G. A., Goya, P., et al. (2012) · ChemMedChem · doi:10.1002/cmdc.201100568 · Cited by 42
Spano, M., Fadda, P., Fratta, W., & Fattore, L. (2010) · Current Drug Targets · doi:10.2174/138945010790980295 · Cited by 35
Synthesis and CB1 cannabinoid receptor affinity of 4-alkoxycarbonyl-1,5-diaryl-1,2,3-triazoles
Shu, H., Izenwasser, S., Wade, D., Stevens, E. D., & Trudell, M. L. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.11.110 · Cited by 42
Kruk-Słomka, M., & Biała, G. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.12.023 · Cited by 42
Almeida-Santos, A. F., Gobira, P. H., Rosa, L. C., Guimaraes, F. S., Moreira, F. A., & Aguiar, D. C. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.05.027 · Cited by 41
Striatal adenosine–cannabinoid receptor interactions in rats over‐expressing adenosine A2A receptors
Chiodi, V., Ferrante, A., Ferraro, L., Potenza, R. L., Armida, M., Beggiato, S., Pèzzola, A., Bäder, M., Fuxé, K., Popoli, P., et al. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13421 · Cited by 41
“CB1R is a G-protein–coupled receptor (GPCR) that is targeted by anandamide and 2-arachidonoylglycerol (2- AG), the two major endocannabinoids in the brain, and by delta-9-tetrahydrocannabinol, the main addictive ingredient of marijuana (Di Marzo et al. 2004; Battista et al. 2012).”
BackgroundFranz, F., Jechle, H., Wilde, M., Angerer, V., Huppertz, L. M., Longworth, M., Kassiou, M., Jung, M., & Auwärter, V. (2019) · Forensic Toxicology · doi:10.1007/s11419-018-00462-x · Cited by 41
Healing autism spectrum disorder with cannabinoids: a neuroinflammatory story
Carbone, E., Manduca, A., Cacchione, C., Vicari, S., & Trezza, V. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.12.009 · Cited by 42
Casteels, C., Lauwers, E., Baitar, A., Bormans, G. M., Baekelandt, V., & Laere, K. V. (2009) · Brain Research · doi:10.1016/j.brainres.2009.12.026 · Cited by 41
“The interdependency between CB1 and DA receptors and their high abundance in the striatal system has led to the hypothesis that targeting the CB1 receptor could be of value to improve motor deficits in neurodegenerative motor diseases such as Parkinson's disease (PD) (Di Marzo et al., 2004).”
A new role of anandamide in human sperm: Focus on metabolism
Aquila, S., Guido, C., Laezza, C., Santoro, A., Pezzi, V., Panza, S., Andò, S., & Bifulco, M. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21837 · Cited by 41
Self-citationYasuo, S., & Korf, H. (2010) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2010.11.006 · Cited by 41
Szabó, G., Kiss, R., Páyer-Lengyel, D., Vukics, K., Szikra, J., Baki, A., Molnár, L. M., Fischer, J., & Keserű, G. M. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.05.010 · Cited by 41
Lu, D., Dopart, R., & Kendall, D. A. (2015) · Cell Stress and Chaperones · doi:10.1007/s12192-015-0653-5 · Cited by 40
Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease
Wyrofsky, R. R., McGonigle, P., & Bockstaele, E. J. V. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.966680 · Cited by 40
“The first was N-arachidonylethanolamide (AEA), which was named ‘anandamide’ after the Sanskrit word meaning ‘bliss’ [3,15].”
BackgroundInfluentialZhang, M., Zhang, M., Wang, L., Yu, T.-S., Jiang, S., Jiang, P., Sun, Y., Pi, J., Zhao, R., & Guan, D.-W. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.05.056 · Cited by 40
Metadata
- Authors
- Marzo, V. D., Bifulco, M., & Petrocellis, L. D.
- Affiliations
- Istituto di Chimica Biomolecolare (IT)
- Institute of Applied Science and Intelligent Systems (IT)
- University of Salerno (IT)
- Corresponding author
- Marzo, Vincenzo Di
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-09-01
- Volume
- 3
- Issue
- 9
- Pages
- 771-784
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2087674201
- Cited by
- 1,090
- References
- 161
- Citations by year
- 2026: 25 · 2025: 38 · 2024: 61 · 2023: 48 · 2022: 43 · 2021: 44 · 2020: 49 · 2019: 43 · 2018: 35 · 2017: 41 · 2016: 28 · 2015: 42 · 2014: 38 · 2013: 48 · 2012: 42
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- endocannabinoid system, cannabinoid receptors, cannabinoid therapeutics, drug development, pathological conditions
- MeSH terms
- Animals, Cannabinoids, Cannabis, Clinical Trials as Topic, Enzymes, Humans, Drug Design, Signal Transduction, Receptors, Cannabinoid, Cannabinoid Receptor Modulators, Cannabinoid Receptor Agonists, Cannabinoid Receptor Antagonists, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.